Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Image Guided Therapy in the Treatment of Gliomas
Image Guided Adaptive Multi-modality Therapy in the Treatment of Gliomas
Status: Enrolling
Updated:  8/3/2017
NYU Cancer Institute
mi
from
New York, NY
Image Guided Therapy in the Treatment of Gliomas
Image Guided Adaptive Multi-modality Therapy in the Treatment of Gliomas
Status: Enrolling
Updated: 8/3/2017
NYU Cancer Institute
mi
from
New York, NY
Click here to add this to my saved trials
Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma
Pharmacokinetics of the Chimeric Anti-GD2 Antibody, ch14.18, in Children With High-Risk Neuroblastoma
Status: Enrolling
Updated:  8/3/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma
Pharmacokinetics of the Chimeric Anti-GD2 Antibody, ch14.18, in Children With High-Risk Neuroblastoma
Status: Enrolling
Updated: 8/3/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  8/15/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 8/15/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  8/15/2017
University of California at San Francisco
mi
from
San Francisco, CA
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 8/15/2017
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  8/15/2017
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 8/15/2017
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  8/15/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 8/15/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  8/15/2017
Henry Ford Hospital
mi
from
Detroit, MI
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 8/15/2017
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  8/15/2017
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 8/15/2017
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  8/15/2017
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 8/15/2017
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  8/15/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 8/15/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  8/15/2017
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 8/15/2017
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Radiation Planning Study for High Grade Brain Tumors
3T Versus 1.5T MR Approaches in Target Definition for Malignant Gliomas: Is There a Significant Difference in Tumor Extent and Radiation Treatment Volume?
Status: Enrolling
Updated:  8/21/2017
University of Cincinnati
mi
from
Cincinnati, OH
Radiation Planning Study for High Grade Brain Tumors
3T Versus 1.5T MR Approaches in Target Definition for Malignant Gliomas: Is There a Significant Difference in Tumor Extent and Radiation Treatment Volume?
Status: Enrolling
Updated: 8/21/2017
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  8/25/2017
University of Alabama At Birmingham; Neuro-Oncology
mi
from
Birmingham, AL
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 8/25/2017
University of Alabama At Birmingham; Neuro-Oncology
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  8/25/2017
UCLA
mi
from
Los Angeles, CA
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 8/25/2017
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  8/25/2017
University of Colorado
mi
from
Aurora, CO
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 8/25/2017
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  8/25/2017
Moffitt Cancer Center
mi
from
Tampa, FL
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 8/25/2017
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  8/25/2017
Oncology-Evanston Nthwest Healthcare Kellogg Cancer Care Ctr
mi
from
Evanston, IL
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 8/25/2017
Oncology-Evanston Nthwest Healthcare Kellogg Cancer Care Ctr
mi
from
Evanston, IL
Click here to add this to my saved trials
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  8/25/2017
Henry Ford Health System
mi
from
Detroit, MI
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 8/25/2017
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  8/25/2017
Hatton Research Institutes
mi
from
Cincinnati, OH
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 8/25/2017
Hatton Research Institutes
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  8/25/2017
Sarah Cannon Cancer Center and Research Institute
mi
from
Nashville, TN
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 8/25/2017
Sarah Cannon Cancer Center and Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  8/25/2017
University of Virgina
mi
from
Charlottesville, VA
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 8/25/2017
University of Virgina
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated:  8/25/2017
Prince of Wales Hospital; Department of Medical Oncology
mi
from
Randwick,
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Enrolling
Updated: 8/25/2017
Prince of Wales Hospital; Department of Medical Oncology
mi
from
Randwick,
Click here to add this to my saved trials
Personalized Translational Platform for Biomarker Discovery in Brain Tumors
Personalized Translational Platform for Biomarker Discovery in Brain Tumors
Status: Enrolling
Updated:  8/28/2017
University of California, San Diego
mi
from
San Diego, CA
Personalized Translational Platform for Biomarker Discovery in Brain Tumors
Personalized Translational Platform for Biomarker Discovery in Brain Tumors
Status: Enrolling
Updated: 8/28/2017
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Personalized Translational Platform for Biomarker Discovery in Brain Tumors
Personalized Translational Platform for Biomarker Discovery in Brain Tumors
Status: Enrolling
Updated:  8/28/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Personalized Translational Platform for Biomarker Discovery in Brain Tumors
Personalized Translational Platform for Biomarker Discovery in Brain Tumors
Status: Enrolling
Updated: 8/28/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated:  8/28/2017
Emory University Hospital
mi
from
Atlanta, GA
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated: 8/28/2017
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated:  8/28/2017
North Shore-LIJ Health System
mi
from
Manhasset, NY
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated: 8/28/2017
North Shore-LIJ Health System
mi
from
Manhasset, NY
Click here to add this to my saved trials
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated:  8/28/2017
Columbia University Medical Center
mi
from
New York, NY
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated: 8/28/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated:  8/28/2017
Temple University Hospital
mi
from
Philadelphia, PA
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated: 8/28/2017
Temple University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
SmartCare: Innovations in Caregiving Interventions
SmartCare: Innovations in Caregiving Interventions
Status: Enrolling
Updated:  8/28/2017
University of Pittsburgh School of Nursing
mi
from
Pittsburgh, PA
SmartCare: Innovations in Caregiving Interventions
SmartCare: Innovations in Caregiving Interventions
Status: Enrolling
Updated: 8/28/2017
University of Pittsburgh School of Nursing
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS
MR Imaging of Inflammatory Responses in the Central Nervous System With Ferumoxytol-Enhanced MRI
Status: Enrolling
Updated:  8/30/2017
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS
MR Imaging of Inflammatory Responses in the Central Nervous System With Ferumoxytol-Enhanced MRI
Status: Enrolling
Updated: 8/30/2017
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
New York Medical College
mi
from
Valhalla, NY
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
New York Medical College
mi
from
Valhalla, NY
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Methodist Children's Hospital of South Texas
mi
from
San Antonio, TX
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Methodist Children's Hospital of South Texas
mi
from
San Antonio, TX
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Oncology Group
mi
from
Arcadia, CA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Oncology Group
mi
from
Arcadia, CA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Hospital Colorado
mi
from
Aurora, CO
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Hospital Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
All Children's Hospital
mi
from
Saint Petersburg, FL
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
All Children's Hospital
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Memorial Hospital
mi
from
Chicago, IL
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Indiana University Cancer Center
mi
from
Indianapolis, IN
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Indiana University Medical Center
mi
from
Indianapolis, IN
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Indiana University Medical Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Children's Hospital-Main Campus
mi
from
New Orleans, LA
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Children's Hospital-Main Campus
mi
from
New Orleans, LA
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Johns Hopkins University
mi
from
Baltimore, MD
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Columbia University Medical Center
mi
from
New York, NY
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  9/1/2017
Oregon Health and Science University
mi
from
Portland, OR
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 9/1/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials